[go: up one dir, main page]

MA29144B1 - ANTIBIOTIC 107891, ITS A1 AND A2 FACTORS, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS CONTAINING IT, AND THEIR USES - Google Patents

ANTIBIOTIC 107891, ITS A1 AND A2 FACTORS, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS CONTAINING IT, AND THEIR USES

Info

Publication number
MA29144B1
MA29144B1 MA30064A MA30064A MA29144B1 MA 29144 B1 MA29144 B1 MA 29144B1 MA 30064 A MA30064 A MA 30064A MA 30064 A MA30064 A MA 30064A MA 29144 B1 MA29144 B1 MA 29144B1
Authority
MA
Morocco
Prior art keywords
antibiotic
factors
antibiotics
pharmaceutically acceptable
activity against
Prior art date
Application number
MA30064A
Other languages
French (fr)
Inventor
Ameriga Lazzarini
Luciano Gastaldo
Gianpaolo Candiani
Ismaela Ciciliato
Daniele Losi
Flavia Marinelli
Enrico Selva
Franco Parenti
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/035,296 external-priority patent/US7319088B2/en
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of MA29144B1 publication Critical patent/MA29144B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE SUBSTANCE ANTIBIOTIQUE D'ORIGINE MICROBIENNE, ARBITRAIREMENT DÉNOMMÉE ANTIBIOTIQUE 107891, QUI EST PRODUITE PAR FERMENTATION DE MICROBISPORA SP. CETTE INVENTION CONCERNE AUSSI ATCC PTA-5024, DES SELS RÉPONDANT AUX NORMES PHARMACEUTIQUES ET DES COMPOSITIONS DE CE COMPOSÉ ET LEUR UTILISATION COMME AGENT ANTIBACTÉRIEN POSSÉDANT UNE ACTIVITÉ INHIBITRICE CONTRE DES MICROBES SENSIBLES. CET ANTIBIOTIQUE 107891, QUI EST UN COMPLEXE COMPRENANT DEUX FACTEURS, DÉNOMMÉE FACTEURS A1 ET A2, POSSÈDE UNE STRUCTURE PEPTIDIQUE CONTENANT DE LA LANTHIONINE ET DE LA MÉTHYLLANTHIONINE COMME CONSTITUANTS QUI SONT DES CARACTÉRISTIQUES HABITUELLES DES ANTIBIOTIQUES DU GROUPE DES LANTIBIOTIQUES. L'ANTIBIOTIQUE 10891 ET SES FACTEURS A1 ET A2 PRÉSENTENT UNE BONNE ACTIVITÉ ANTIBACTÉRIENNE CONTRE LA BACTÉRIE GRAM-POSITIF COMPRENANT DES SOUCHES RÉSISTANTES À LA MÉTHICILLINE ET À LA VANCOMYCINE, DE MÊME QUE CET ANTIBIOTIQUE EST ACTIF CONTRE QUELQUES BACTÉRIE GRAM-NÉGATIF TELLES QUE DES ESPÈCES M. CATHARRALIS, NEISSERIA ET H. INFLUENZAE ET MYCOBACTERIA.THE INVENTION CONCERNS AN ANTIBIOTIC SUBSTANCE OF MICROBIAL ORIGIN, ARBITRATLY DESCRIBED ANTIBIOTIC 107891, WHICH IS PRODUCED BY FERMENTATION OF MICROBISPORA SP. THIS INVENTION ALSO INVOLVES ATCC PTA-5024, PHARMACEUTICAL STANDARD SALTS AND COMPOSITIONS THEREOF, AND THEIR USE AS ANTIBACTERIAL AGENT HAVING AN INHIBITORY ACTIVITY AGAINST SENSITIVE MICROBES. THIS ANTIBIOTIC 107891, WHICH IS A COMPLEX COMPRISING TWO FACTORS, NAMED FACTORS A1 AND A2, HAS A PEPTIDE STRUCTURE CONTAINING LANTHIONIN AND METHYLLANTHIONIN AS CONSTITUENTS THAT ARE HABITUAL FEATURES OF THE ANTIBIOTICS OF THE GROUP OF LANTIBIOTICS. ANTIBIOTIC 10891 AND ITS A1 AND A2 FACTORS HAVE GOOD ANTIBACTERIAL ACTIVITY AGAINST GRAM-POSITIVE BACTERIA COMPRISING METHICILLIN AND VANCOMYCIN RESISTANT STRAINS, AND ANTIBIOTICS AGAINST A FEW GRAM-NEGATIVE BACTERIA SUCH AS SPECIES M. CATHARRALIS, NEISSERIA AND H. INFLUENZAE AND MYCOBACTERIA.

MA30064A 2005-01-12 2007-07-12 ANTIBIOTIC 107891, ITS A1 AND A2 FACTORS, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS CONTAINING IT, AND THEIR USES MA29144B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/035,296 US7319088B2 (en) 2003-07-18 2005-01-12 Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof

Publications (1)

Publication Number Publication Date
MA29144B1 true MA29144B1 (en) 2008-01-02

Family

ID=38346011

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30064A MA29144B1 (en) 2005-01-12 2007-07-12 ANTIBIOTIC 107891, ITS A1 AND A2 FACTORS, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS CONTAINING IT, AND THEIR USES

Country Status (6)

Country Link
KR (1) KR100892655B1 (en)
CY (1) CY1113157T1 (en)
MA (1) MA29144B1 (en)
PT (1) PT1855705E (en)
UA (1) UA87546C2 (en)
ZA (1) ZA200705494B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351687B2 (en) * 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218362B1 (en) * 1997-09-08 2001-04-17 Universite Laval Lantibiotic from Streptococcus mutans and uses thereof

Also Published As

Publication number Publication date
KR20070098903A (en) 2007-10-05
PT1855705E (en) 2012-10-16
KR100892655B1 (en) 2009-04-15
UA87546C2 (en) 2009-07-27
CY1113157T1 (en) 2016-04-13
ZA200705494B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
Wisplinghoff et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities
Zipfel et al. Complement evasion of pathogens: common strategies are shared by diverse organisms
MA29237B1 (en) ANTIBIOTICS 107891, ITS A1 AND A2 FACTORS, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, COMPOSITIONS CONTAINING THE SAME, AND USES THEREOF
EA200600280A1 (en) COMPOSITIONS BASED ON DERIVATIVES OF LIPOPEPTID ANTIBIOTICS AND METHODS OF THEIR APPLICATION
Liu et al. Diversity and antimicrobial potential of Actinobacteria isolated from diverse marine sponges along the Beibu Gulf of the South China Sea
MX336242B (en) The use of type-b lantibiotic-based compounds having antimicrobial activity.
Castanheira et al. Azole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression
Barber et al. Therapeutic options for vancomycin-resistant enterococcal bacteremia
Jones et al. Reducing the bottleneck in discovery of novel antibiotics
Kamou et al. Investigating the compatibility of the biocontrol agent Clonostachys rosea IK726 with prodigiosin-producing Serratia rubidaea S55 and phenazine-producing Pseudomonas chlororaphis ToZa7
Sweeney et al. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus
MXPA06000691A (en) Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof.
Hemmersbach-Miller et al. Updates on Nocardia skin and soft tissue infections in solid organ transplantation
WO2007075177A3 (en) Antibiotics targeting mreb
Wang et al. VraCP regulates cell wall metabolism and antibiotic resistance in vancomycin-intermediate Staphylococcus aureus strain Mu50
Projan et al. Antibiotic resistance in the staphylococci
MA29144B1 (en) ANTIBIOTIC 107891, ITS A1 AND A2 FACTORS, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS CONTAINING IT, AND THEIR USES
Treviño-Rangel et al. First report of Candida bracarensis in Mexico: hydrolytic enzymes and antifungal susceptibility pattern
Ducharlet et al. Recurrent M ycobacterium haemophilum in a renal transplant recipient
TNSN07262A1 (en) ANTIBIOTICS 107891, ITS A1 AND A2 FACTORS, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS CONTAINING SAME, AND USES THEREOF
E. Gustafson, Sean D. Cox, Yoon C. Liew, S. Grant Wyllie, John R. Warmington The bacterial multiple antibiotic resistant (Mar) phenotype leads to increased tolerance to tea tree oil
Chakraborty et al. Antibiotic-active heterotrophic Firmicutes sheltered in seaweeds: can they add new dimensions to future antimicrobial agents?
Arhin et al. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters
Magalhães Ecological Interactions in Pseudomonas Aeruginosa-Staphylococcus Aureus Mixed Biofilms: Deciphering Co-Infection in Cystic Fibrosis Airways
Arooj et al. Texiobactin, a Potent Killer of Antibiotic Resistant Pathogens